NewLink Genetics Corporation (NASDAQ:NLNK) Files An 8-K Other Events

NewLink Genetics Corporation (NASDAQ:NLNK) Files An 8-K Other Events

Story continues below

Item 8.01. Other Events.

On May 18, 2017, NewLink Genetics Corporation (the “Company”)
issued a press release titled “Data from Clinical Study of
NewLink Genetics IDO Pathway Inhibitor, Indoximod, to Be
Presented at the 22nd European Hematology Association Congress.”
The press release is attached hereto as Exhibit 99.1 and
incorporated herein by reference.
Section 9 – Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit Number
Description
99.1
Press Release, dated May 18, 2017, entitled Data from
Clinical Study of NewLink Genetics
IDO Pathway Inhibitor, Indoximod, to Be Presented at
the 22nd European Hematology Association
Congress


About NewLink Genetics Corporation (NASDAQ:NLNK)

NewLink Genetics Corporation is a biopharmaceutical company focused on discovering, developing and commercializing immunotherapeutic products for cancer treatment. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications. Its biologic product candidates are based on its HyperAcute immunotherapy technology platform, which is designed to stimulate the human immune system. Algenpantucel-L is its clinically advanced product candidate for patients with pancreatic cancer. Its additional HyperAcute cellular HyperAcute Cellular Immunotherapy product candidates in clinical development include tergenpumatucel-L and dorgenmeltucel-L for patients with advanced lung cancer and melanoma. It has two small-molecule product candidates in clinical development: GDC-0919 and indoximod. These product candidates are indoleamine-2, 3-dioxygenase (IDO) pathway inhibitors and focus on breaking the immune system’s tolerance to cancer.

NewLink Genetics Corporation (NASDAQ:NLNK) Recent Trading Information

NewLink Genetics Corporation (NASDAQ:NLNK) closed its last trading session down -0.25 at 16.10 with 610,253 shares trading hands.

An ad to help with our costs